BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing
With 74% Institutional Ownership, ResMed Inc. (NYSE:RMD) Is a Favorite Amongst the Big Guns
ResMed Initiated at Hold by Stifel
ResMed Price Target Announced at $250.00/Share by Stifel
5 Solid Dividend Growth Stocks to Buy Now
Scoop Up These 3 GARP Stocks to Receive Handsome Returns
Here Are the Top 10 ASX 200 Shares Today
3 Excellent ASX 200 Blue Chip Shares to Buy in 2025
What's the Diagnosis for ASX Healthcare Shares in 2025?
Here's the Outlook on ResMed Shares in 2025
Resmed Inc Chairman Sells Shares Under Trading Plan
Express News | Resmed Inc-Proposed Sale of Securities Under Rule 144
2 ASX Healthcare Shares That Are Screaming Buys in December
PDCO Stock Gains Despite Q2 Earnings Miss and Lower Margins
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
ResMed Inc Adjusts CHESS Depositary Interests in November
Is ResMed Inc.'s (NYSE:RMD) Recent Performance Tethered To Its Attractive Financial Prospects?
Insider Activity: Resmed Inc Director's Share Sales
ABT Stock Benefits From First Patient Procedures With TAVI System
ResMed Inc's Peter Farrell Alters Stock Holdings